SEC Form 4 · accession 0000919574-18-004961
Strongbridge Biopharma plc · SBBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jul 24, 2018
Accepted (ET)
Jul 27, 2018 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001634432
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, $0.01 par valueF1 | Jul 24, 2018 | P | 150,000 | $4.9151 | A | 5,614,734 | D | |
| Ordinary Shares, $0.01 par valueF1 | Jul 26, 2018 | P | 39,800 | $4.9429 | A | 5,654,534 | D | |
| Ordinary Shares, $0.01 par valueF1 | Jul 27, 2018 | P | 116,900 | $4.6283 | A | 5,771,434 | D | |
| Ordinary Shares, $0.01 par valueF1 | Jul 27, 2018 | P | 92,400 | $4.85 | A | 5,863,384 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares represent (a) 5,549,678 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 314,156 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.